Altavilla, Giuseppe

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 5,489

Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions

Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S. S., & Doetsch, P. W. (2013) · PLoS ONE

Mitochondrial Function and PathologyMetal complexes synthesis and properties

Cited by 777

Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments

Mondello, P., Mian, M., Pitini, V., Cuzzocrea, S., Sindoni, A., Galletti, M., Mandolfino, M., Santoro, D., Mondello, S., Aloisi, C., et al. (2016) · Current Oncology

Thyroid Disorders and TreatmentsThyroid Cancer Diagnosis and Treatment

Cited by 11